Why your LDL - “bad cholesterol” - level does not tell the true story...
Atherogenic dyslipidemia – the more complete lipid profile
How common is atherogenic dyslipidemia?
1. Mozaffarian, D., et al., Heart disease and stroke statistics--2015 update: a report from the American Heart Association. Circulation, 2015. 131(4): p. e29-322.
2. National Cholesterol Education Program Expert Panel on Detection, E. and A. Treatment of High Blood Cholesterol in, Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 2002. 106(25): p. 3143-421.
3. Brunzell, J.D., et al., Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation. J Am Coll Cardiol, 2008. 51(15): p. 1512-24.
4. Stone, N.J., et al., 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol, 2014. 63(25 Pt B): p. 2889-934.
5. LaRosa, J.C., J. He, and S. Vupputuri, Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA, 1999. 282(24): p. 2340-6.
6. Libby, P., The forgotten majority: unfinished business in cardiovascular risk reduction. J Am Coll Cardiol, 2005. 46(7): p. 1225-8.
7. LaRosa, J.C., et al., Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med, 2005. 352(14): p. 1425-35.
8. Colquhoun, D., et al., Prevalence of mixed dyslipidemia among Australian patients undergoing lipid-modifying therapy. Exp Clin Cardiol, 2013. 18(1): p. e32-6.
9. Hausenloy, D.J. and D.M. Yellon, Enhancing cardiovascular disease risk reduction: raising high-density lipoprotein levels. Curr Opin Cardiol, 2009. 24(5): p. 473-82.
10. Fruchart, J.C., et al., The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol, 2008. 102(10 Suppl): p. 1K-34K.
11. Sampson, U.K., S. Fazio, and M.F. Linton, Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges. Curr Atheroscler Rep, 2012. 14(1): p. 1-10.
12. Fruchart, J.C., et al., Residual macrovascular risk in 2013: what have we learned? Cardiovasc Diabetol, 2014. 13: p. 26.
13. Chapman, M.J., et al., Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J, 2011. 32(11): p. 1345-61.
14. Alagona, P., Jr., Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy. Am J Manag Care, 2009. 15(3 Suppl): p. S65-73.
15. Faergeman, O., et al., Plasma triglycerides and cardiovascular events in the Treating to New Targets and Incremental Decrease in End-Points through Aggressive Lipid Lowering trials of statins in patients with coronary artery disease. Am J Cardiol, 2009. 104(4): p. 459-63.
16. Griffin, B.A., et al., Role of plasma triglyceride in the regulation of plasma low density lipoprotein (LDL) subfractions: relative contribution of small, dense LDL to coronary heart disease risk. Atherosclerosis, 1994. 106(2): p. 241-53.
17. Toth, P.P., et al., Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets. Atherosclerosis, 2014. 235(2): p. 585-91.
18. Sachdeva, A., et al., Lipid levels in patients hospitalized with coronary artery disease: an analysis of 136,905 hospitalizations in Get With The Guidelines. Am Heart J, 2009. 157(1): p. 111-117 e2.
19. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation, 2002. 106(25): p. 3143-421.
20. Rubins, H.B., et al., Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. Am J Cardiol, 1995. 75(17): p. 1196-201.
21. Gonzalez-Pacheco, H., et al., Prevalence of conventional risk factors and lipid profiles in patients with acute coronary syndrome and significant coronary disease. Ther Clin Risk Manag, 2014. 10: p. 815-23.
22. Case, C.C., et al., Management of persons with high risk of coronary heart disease but low serum low-density lipoprotein cholesterol. Am J Cardiol, 2003. 91(9): p. 1134-6.
23. Stamler, J., et al., Serum cholesterol. Doing the right thing. Circulation, 1993. 88(4 Pt 1): p. 1954-60.
24. Schaefer, E.J., et al., Effects of gender and menopausal status on the association of apolipoprotein E phenotype with plasma lipoprotein levels. Results from the Framingham Offspring Study. Arterioscler Thromb, 1994. 14(7): p. 1105-13.
25. Krauss, R.M., Lipids and lipoproteins in patients with type 2 diabetes. Diabetes Care, 2004. 27(6): p. 1496-504.
26. Nesto, R.W., Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome. Am J Cardiovasc Drugs, 2005. 5(6): p. 379-87.
27. Austin, M.A., et al., Low-density lipoprotein subclass patterns and risk of myocardial infarction. JAMA, 1988. 260(13): p. 1917-21.
28. Austin, M.A., et al., Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. Circulation, 1990. 82(2): p. 495-506.
29. Hoenig, M.R., Implications of the obesity epidemic for lipid-lowering therapy: non-HDL cholesterol should replace LDL cholesterol as the primary therapeutic target. Vasc Health Risk Manag, 2008. 4(1): p. 143-56.
30. Grundy, S.M., et al., Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation, 2005. 112(17): p. 2735-52.
31. Alberti, K.G., et al., Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation, 2009. 120(16): p. 1640-5.
32. Gordon, T., et al., High density lipoprotein as a protective factor against coronary heart disease. The Framingham Study. Am J Med, 1977. 62(5): p. 707-14.
33. Wilson, P.W., R.D. Abbott, and W.P. Castelli, High density lipoprotein cholesterol and mortality. The Framingham Heart Study. Arteriosclerosis, 1988. 8(6): p. 737-41.
34. Boden, W.E., High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial. Am J Cardiol, 2000. 86(12A): p. 19L-22L.
35. Gordon, D.J., et al., High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies. Circulation, 1989. 79(1): p. 8-15.
36. Assmann, G., et al., High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis, 1996. 124 Suppl: p. S11-20.
37. Castelli, W.P., et al., Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study. JAMA, 1986. 256(20): p. 2835-8.
38. Miller, M., et al., Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association. Circulation, 2011. 123(20): p. 2292-333.
39. Nordestgaard, B.G. and A. Varbo, Triglycerides and cardiovascular disease. Lancet, 2014. 384(9943): p. 626-35.
40. Do, R., et al., Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet, 2013. 45(11): p. 1345-52.
41. Triglyceride Coronary Disease Genetics, C., et al., Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies. Lancet, 2010. 375(9726): p. 1634-9.
42. Miller, M., et al., Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial. J Am Coll Cardiol, 2008. 51(7): p. 724-30.
43. Liu, J., et al., Effects of blood triglycerides on cardiovascular and all-cause mortality: a systematic review and meta-analysis of 61 prospective studies. Lipids Health Dis, 2013. 12: p. 159.
44. Austin, M.A., J.E. Hokanson, and K.L. Edwards, Hypertriglyceridemia as a cardiovascular risk factor. Am J Cardiol, 1998. 81(4A): p. 7B-12B.
45. Borena, W., et al., Serum triglycerides and cancer risk in the metabolic syndrome and cancer (Me-Can) collaborative study. Cancer Causes Control, 2011. 22(2): p. 291-9.
46. Davidson, M.H., et al., Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol, 2011. 5(5): p. 338-67.
47. Pischon, T., et al., Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men. Circulation, 2005. 112(22): p. 3375-83.
48. Krauss, R.M., Lipoprotein subfractions and cardiovascular disease risk. Curr Opin Lipidol, 2010. 21(4): p. 305-11.
49. Ip, S., et al., Systematic review: association of low-density lipoprotein subfractions with cardiovascular outcomes. Ann Intern Med, 2009. 150(7): p. 474-84.
50. Parish, S., et al., Lipids and lipoproteins and risk of different vascular events in the MRC/BHF Heart Protection Study. Circulation, 2012. 125(20): p. 2469-78.
51. Williams, P.T., et al., Comparison of four methods of analysis of lipoprotein particle subfractions for their association with angiographic progression of coronary artery disease. Atherosclerosis, 2014. 233(2): p. 713-20.
52. Toth, P.P., D. Potter, and E.E. Ming, Prevalence of lipid abnormalities in the United States: the National Health and Nutrition Examination Survey 2003-2006. J Clin Lipidol, 2012. 6(4): p. 325-30.
53. Ghandehari, H., S. Kamal-Bahl, and N.D. Wong, Prevalence and extent of dyslipidemia and recommended lipid levels in US adults with and without cardiovascular comorbidities: the National Health and Nutrition Examination Survey 2003-2004. Am Heart J, 2008. 156(1): p. 112-9.
54. Ford, E.S., et al., Hypertriglyceridemia and its pharmacologic treatment among US adults. Arch Intern Med, 2009. 169(6): p. 572-8.
55. Bruckert, E., et al., High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr Med Res Opin, 2005. 21(12): p. 1927-34.
56. Plana, N., et al., Prevalence of atherogenic dyslipidemia in primary care patients at moderate-very high risk of cardiovascular disease. Cardiovascular risk perception. Clin Investig Arterioscler, 2014. 26(6): p. 274-84.
57. Flegal, K.M., et al., Prevalence and trends in obesity among US adults, 1999-2008. JAMA, 2010. 303(3): p. 235-41.
58. Ford, E.S., Prevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the U.S. Diabetes Care, 2005. 28(11): p. 2745-9.
59. Aguilar, M., et al., Prevalence of the Metabolic Syndrome in the United States, 2003-2012. JAMA, 2015. 313(19): p. 1973-1974.
60. Ioannou, G.N., C.L. Bryson, and E.J. Boyko, Prevalence and trends of insulin resistance, impaired fasting glucose, and diabetes. J Diabetes Complications, 2007. 21(6): p. 363-70.
61. Ghandehari, H., et al., Abdominal obesity and the spectrum of global cardiometabolic risks in US adults. Int J Obes (Lond), 2009. 33(2): p. 239-48.
62. Li, C., et al., Increasing trends in waist circumference and abdominal obesity among US adults. Obesity (Silver Spring), 2007. 15(1): p. 216-24.
63. Beltran-Sanchez, H., et al., Prevalence and trends of metabolic syndrome in the adult U.S. population, 1999-2010. J Am Coll Cardiol, 2013. 62(8): p. 697-703.
64. Bosomworth, N.J., Approach to identifying and managing atherogenic dyslipidemia: a metabolic consequence of obesity and diabetes. Can Fam Physician, 2013. 59(11): p. 1169-80.
Medical Writer & Nutritionist
University of Stockholm & Karolinska Institute, Sweden
Baylor University, TX, USA
Latest from Monica
- Hematocrit (blood thickness) elevation following testosterone therapy – does it increase risk of blood clots?
- Is there a protective role of testosterone against high-grade prostate cancer?
- Effects of testosterone treatment on body fat, lean mass, symptoms and leptin resistance in obese men on a calorie-restricted diet
- Long-Term Testosterone Therapy Improves Cardiometabolic Function and Reduces Risk of Cardiovascular Disease: Real-Life Results
- Exercise – much more than just a calorie burning tool
- Long-Term Testosterone Therapy Improves Cardiometabolic Function and Reduces Risk of Cardiovascular Disease: Real-Life Results
- Testosterone treatment is NOT associated with risk of adverse cardiovascular events – the RHYME study
- Video Summary: Testosterone Deficiency and Treatment - International Expert Consensus Resolutions
- Testosterone Deficiency and Treatment - the FACTS
- Real-life experience of continuous long-term testosterone therapy on anthropometric, endocrine and metabolic parameters for up to 10 years